Pharma results may benefit from rupee depreciation, particularly for exporters, though elevated freight and input costs remain risks. InCred sees potential pressure at Dr Reddy’s, Divi’s, Lupin, Cipla, Torrent Pharma and Blue Jet Healthcare in Q2FY27. Check its top stock picks in the segment.
Pharma results may benefit from rupee depreciation, particularly for exporters, though elevated freight and input costs remain risks. InCred sees potential pressure at Dr Reddy’s, Divi’s, Lupin, Cipla, Torrent Pharma and Blue Jet Healthcare in Q2FY27. Check its top stock picks in the segment.
<iframe src="https://hindustansphere.com/embed/cluster/65590e3d4888d424f2fb686ff84b17b9d5f25678" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Pharma stocks to buy ahead of Q2 results: Acutaas Chemicals, Mankind Pharma, Ipca Labs - Max upside? Target price"></iframe>
